Neupro Patch Could See Restless Legs Indication In Second Half 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB filed the Parkinson's disease therapy for restless legs syndrome with FDA in October, firm tells DAILY.
You may also be interested in...
UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
UCB Recalls Neupro Patches; U.S. Projected Out Of Stock By Late April
Failure to meet manufacturing specs, not contamination or toxicity, forced recall, Belgian pharma says.